A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 at the putative RP2D(s) (Part 2: Dose Expansion).